Introducing the first hepcidin mimetic for the treatment of erythrocytosis in adults with polycythemia vera (PV)^1,2

A new era in PV starts now

MIMRYLO™ (rusfertide) maintained hematocrit (HCT) control below 45%, reduced reliance on rescue phlebotomies, and reduced fatigue vs the control arm¹

MIMRYLO is the first and only hepcidin mimetic for the treatment of erythrocytosis in adults with PV^1,2

MIMRYLO has a novel mechanism of action

A hepcidin mimetic that targets iron regulation¹

See How MIMRYLO Works

See how MIMRYLO performed in the largest pivotal trial in PV

Explore HCT control out to 52 weeks^1,3-5

Discover the Data

MIMRYLO has a favorable safety profile

See common adverse reactions in a pivotal trial¹

Explore the Safety Profile

Discover important information for treating your patients with MIMRYLO

Key information on dose adjustments, monitoring details, and maintenance

Learn About Dosing

HCT=hematocrit; PV=polycythemia vera.

All individuals in images are actor portrayals.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

New or Worsening Thrombocytosis: MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Injection-Site Reactions: Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Embryo-Fetal Toxicity: Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.

Females and Males of Reproductive Potential

Pregnancy Testing: Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
Contraception: Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see MIMRYLO (rusfertide) full Prescribing Information.

A new era in PV starts now

MIMRYLO is the first and only hepcidin mimetic for the treatment of erythrocytosis in adults with PV^1,2

Discover important information for treating your patients with MIMRYLO

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION

MIMRYLO is the first and only hepcidin mimetic for the treatment of erythrocytosis in adults with PV1,2

Discover important information for treating your patients with MIMRYLO

IMPORTANT SAFETY INFORMATION AND INDICATION

MIMRYLO is the first and only hepcidin mimetic for the treatment of erythrocytosis in adults with PV^1,2